NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Published on November 16, 2009
OMB APPROVAL | ||
OMB Number: 3235-0058
|
||
Expires: May 31, 2012 |
||
Estimated
average burden
hours per response ... 2.50 |
||
SEC FILE NUMBER | ||
CUSIP NUMBER | ||
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF
LATE FILING
(Check one): | o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR | |||||
For Period Ended: | September 30, 2009 | |||||
o Transition Report on Form 10-K | ||||||
o Transition Report on Form 20-F | ||||||
o Transition Report on Form 11-K | ||||||
o Transition Report on Form 10-Q | ||||||
o Transition Report on Form N-SAR | ||||||
For the Transition Period Ended: | ||||||
Read Instruction
(on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be
construed to imply that the Commission has verified any information contained
herein.
If the notification
relates to a portion of the filing checked above, identify the Item(s) to which
the notification relates:
PART I
REGISTRANT INFORMATION
NeoGenomics, Inc.
Full Name of
Registrant
Not applicable
Former Name if
Applicable
12701 Commonwealth
Drive, Suite 9
Address of Principal
Executive Office (Street and Number)
Fort Myers, Florida
33913
City, State and Zip
Code
PART II
RULES 12b-25(b) AND (c)
If the subject report
could not be filed without unreasonable effort or expense and the registrant
seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)
þ
|
|||||
(a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense | ||||
(b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | ||||
(c) | The accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III
NARRATIVE
State below in
reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the
transition report or portion thereof, could not be filed within the prescribed
time period.
The Quarterly Report
on Form 10-Q for the quarterly period ended September 30, 2009 of NeoGenomics,
Inc. (the Company) could not be filed within the prescribed time period
because the Company requires additional time for the preparation and review of
the Form 10-Q.
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
(Attach extra
Sheets if Needed)
PART IV OTHER INFORMATION
(1) | Name and telephone number of person to contact in regard to this notification |
Jerome J. Dvonch | 239 | 768-0600 | ||
(Name) |
(Area Code) | (Telephone Number) |
(2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | |
Yes þ No o | ||
(3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | |
Yes þ No o | ||
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | ||
Please see the Companys unaudited consolidated balance sheet as of September
30, 2009 and December 31, 2008, the unaudited consolidated statements of
operations of the Company for the three and nine months ended September 30, 2009
and September 30, 2008 and the unaudited consolidated statements of cash flows
of the Company for the nine months ended September 30, 2009 and September 30,
2008 (the Financial Statements), incorporated by reference herein, which were
included in the press release attached as Exhibit 99.1 to the Companys Current
Report on Form 8-K filed with the Securities and Exchange Commission on November
3, 2009. The Financial Statements, among other things, reflect that during the
nine months ended September 30, 2009, the Companys revenues increased to
$21,669,645 from $14,094,959 during the nine months ended September 30, 2008.
NeoGenomics, Inc.
(Name of Registrant
as Specified in Charter)
has caused this
notification to be signed on its behalf by the undersigned hereunto duly
authorized.
Date
|
November 16, 2009 | By | /s/ Jerome J. Dvonch | |||
Director of Finance and Principal Accounting Officer | ||||||